Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients with Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers

Next Previous
X
Search
Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-559, an Oral Inhibitor of the Helicase DHX9, in Patients with Locally Advanced or Metastatic Solid Tumors and Molecularly Defined Cancers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATX 559 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Accent Therapeutics

    • Most Recent Events

    • 11 Dec 2024 According to Accent Therapeutics Media release, company today announced that the first patient has been dosed in this trial.
    • 28 Oct 2024 Status changed from not yet recruiting to recruiting.
    • 24 Oct 2024 According to Accent Therapeutics Media release, first patient dosed anticipated in Q4 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top